TL;DR
This study investigates whether all patients with suspicious prostate lesions require both targeted biopsy (TB) and systematic biopsy (SB). The researchers found that by combining Prostate-Specific Antigen Density (PSAD) and PI-RADS scores, clinicians can confidently identify patients who can safely undergo only targeted biopsy, thus reducing unnecessary procedures and patient discomfort.
What Problem Does This Paper Address?
Prostate cancer (PCa) diagnosis typically involves prostate biopsy. Multiparametric MRI (mpMRI) has significantly improved the detection of suspicious lesions, leading to the development of MRI-TRUS fusion targeted biopsy (TB). While TB is precise, omitting systematic biopsy (SB) can lead to missed diagnoses. Conversely, combining TB with SB (TB+SB) increases PCa detection but also risks overdiagnosis of indolent cancers, leading to patient discomfort, increased risk of complications (infection, bleeding), and potential surgical difficulties due to tissue adhesion. This paper addresses the challenge of optimizing the biopsy strategy: how to maximize PCa detection while minimizing unnecessary procedures and their associated risks, particularly in the era of advanced MRI-TRUS fusion technology. The core question is whether a universal TB+SB approach is always necessary, or if patient stratification based on clinical indicators can allow for a more tailored approach, potentially omitting SB in select cases.
Methods
The study employed a retrospective design, analyzing data from 340 biopsy-naïve men with suspicious prostate lesions (PI-RADS ≥ 3) and PSA < 20 ng/mL who underwent both MRI-TRUS fusion targeted biopsy (TB) and systematic biopsy (SB) at Beijing Hospital. The TB+SB approach was considered the gold standard. The primary outcome was to identify independent predictors for a "valid diagnosis" when only TB was performed (mono-TB), meaning the pathological outcome was consistent with the TB+SB results. Secondary outcomes included exploring predictive factors for detecting prostate cancer (PCa) and clinically significant PCa (csPCa) with both mono-TB and TB+SB.
Statistical analyses included univariate and multivariate logistic regression to identify predictors of valid diagnosis. Receiver Operating Characteristic (ROC) curve analysis was used to evaluate the predictive value of individual factors and their combinations. A weighted kappa test was used to assess the consistency between TB and TB+SB modes.
Datasets
The study utilized data from 340 biopsy-naïve patients who underwent MRI-TRUS fusion TB + SB at Beijing Hospital between January 2018 and September 2022. This dataset was collected as part of an ongoing prospective trial. No new datasets were introduced.
Key Insights and Ideas
- PSAD and PI-RADS are powerful stratifiers: The study strongly suggests that combining PSAD and PI-RADS scores can effectively stratify patients, guiding the decision of whether to perform SB.
- Higher scores mean higher confidence in mono-TB: Patients with higher PSAD and PI-RADS scores are more likely to have a valid diagnosis with mono-TB, indicating greater confidence in omitting SB for these individuals.
- Balancing benefits and risks: The findings offer a pathway to optimize prostate biopsy protocols, aiming to reduce the burden of overdiagnosis and complications associated with unnecessary SB, while still ensuring adequate cancer detection.
- Mono-TB can be reliable in specific subgroups: For patients with favorable PSAD and PI-RADS combinations, mono-TB demonstrated good consistency with the gold standard TB+SB, suggesting it can be a safe and effective alternative.
Key Results
- Valid diagnosis rate for mono-TB: Among the 178 patients diagnosed with PCa, the valid diagnosis rate for mono-TB was 77.53%.
- Predictive power of PSAD and PI-RADS: Both PSAD and PI-RADS were identified as independent predictors for a valid diagnosis with mono-TB.
- ROC analysis: The combination of PSAD and PI-RADS yielded the highest AUC value (0.803) in predicting the validity of mono-TB diagnosis, with an optimal threshold showing high sensitivity and specificity.
- Stratification effectiveness: When patients were stratified into "favorable" and "non-favorable" groups based on PSAD and PI-RADS, the consistency between mono-TB and TB+SB results was significantly higher in the "favorable" group (Kappa value 0.762 vs. 0.333).
- Detection rates: While TB+SB detected more PCa and csPCa overall, mono-TB showed a higher detection rate for cisPCa (clinically insignificant PCa), aligning with the goal of reducing overdiagnosis.
Limitations and Future Work
The authors acknowledge several limitations:
- Single-center study: Data were obtained from a single institution, limiting generalizability.
- Cognitive fusion bias: The use of cognitive fusion for TB, rather than solely software fusion, may introduce bias in biopsy localization.
- Potential interference: TB might create bleeding tracks that could interfere with the blinding of SB performers.
Future work should focus on:
- Large-scale randomized controlled trials: To verify these findings and establish robust evidence for the proposed stratification strategy.
- Exploring other biomarkers: Investigating the utility of other clinical biomarkers, such as prostate-specific membrane antigen (PSMA) PET/CT, in conjunction with MRI findings, to further refine patient stratification.
- Prospective validation: The proposed strategy requires prospective validation to confirm its real-world effectiveness and safety.
Summary updated